Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing and Provides Update on ADX-629 for COVID-19

Aldeyra Therapeutics to Advance ADX-1612 to Clinical Testing and Provides Update on ADX-629 for COVID-19

Shots:

  • Aldeyra has reported the planned advancement of ADX-1612 (HSP90 inhibitor) to clinical testing for COVID-19, and provided an update on ADX-629 (RASP inhibitor) for COVID-19 and other inflammatory diseases
  • ADX-1612 has demonstrated nanomolar potency like or greater than Gilead’s remdesivir in an in vitro model and acts by inhibiting the proteins associated with viral replication and infection, thus enhance the activity of other antiviral drugs to treat COVID-19. Pending FDA feedback, an IND submission for ADX-1612 is expected in Q3’20 and the therapy is also being evaluated in P-II EUDARIO study for ovarian ancer
  • ADX-629 has accepted for BARDA CoronaWatch meeting, completed its pre-IND submission with the Pulmonary Division of the FDA with its expected submission of an IND in Jun’2020. ADX-629 has demonstrated reductions across a variety of TH1, TH2, and TH17 inflammatory cytokines, while upregulating the IL-10 and also being evaluated in P-IIa clinical study for psoriasis and atopic asthma, expected to be initiated in H2’20

Click here to­ read full press release/ article | Ref: Aldeyra | Image: Aldeyra